PLXDC1 and neoplasm: In this study, we demonstrated that the HA-labeled CH-NPs incorporating PLXDC1 siRNA (HA-CH-NP/PLXDC1 siRNA) can be used for targeted siRNA delivery to the tumor vasculature (Figure 1(A)).